



Regd. Office:

'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India.

Phone: +91-79-2686 8100 (20 Lines) Fax: +91-79-2686 2368 www.zvduscadila.com

CIN:L24230GJ1995PLC025878

BSE Limited

1st Floor, P.J. Towers

Dalal Street

Mumbai - 400 001

Exchange Plaza, 5th Floor, Plot No. C/1, G Block,

Bandra-Kurla Complex, Bandra (East)

National Stock Exchange of India Limited

Mumbai - 400 051

Kind Attn.:

Mr. Sanjay Golecha /

Mr. Gopalkrishnan

Kind Attn.:

Famroze Pochara

Asst. Vice President

Date:

February 17, 2017

Re.:

Press Release

Dear Sir / Madam,

We enclose herewith a copy of press release dated February 17, 2017, titled "Zydus receives final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray.

The contents of the press release give full details.

AHMEDABA

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully, For, Cadila Healthcare Limited

Upen H. Shah
Company Secretary

Encl.: As above



Press Release

Press Release



Press Release

Press Release

Press Release

Zydus receives final approval from the USFDA for Fluconazole Tablets USP and Clobetasol Propionate Spray

Ahmedabad, 17 February 2017

Zydus Cadila has received the final approval from the USFDA to market Fluconazole Tablets USP in strengths of 50 mg, 100 mg, 150 mg and 200 mg and Clobetasol Propionate Spray, 0.05%.

Fluconazole Tablets USP which are used to treat fungal infections will be produced at the group's formulations manufacturing facility at Baddi.

Clobetasol Propionate Spray, used in the treatment of various skin disorders will be manufactured at the group's dedicated Topical plant located at Changodar, Ahmedabad.

The group now has more than 105 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.